The LTC Innovation Blog

The sale of Omnicare's LTC pharmacy business is not just another healthcare transaction. It is a clear signal that the the economic and operational realities facing long-term care (LTC) pharmacy are shifting in ways that affect every type of provider in the market, big or small. On May 13, 2026, the U.S. Bankruptcy Court for the Northern District of Texas approved the $250 million sale of Omnicare — a subsidiary of CVS Health - to GenieRx Holdings LLC, a joint partnership between private investment firm Milrose Capital LLC and healthcare investment and management firm Integro Asset Management LLC, operating as Integro Healthcare Services. The transaction is expected to close later in 2026, pending regulatory approval, with Omnicare continuing to serve its clients through the transition period. Omnicare filed for Chapter 11 bankruptcy in September 2025, citing a combination of legal proceedings and broader financial pressures facing the long-term care pharmacy sector. Those pressures had been building for some time. Omnicare is not the only enterprise in the broader LTC sector to face significant financial strain. Genesis Healthcare, one of the nation's largest skilled nursing facility operators, filed Chapter 11 bankruptcy in July 2025 with $2.3 billion in debt, a signal that the financial pressure is not confined to any single organization but is being felt across the sector. For LTC pharmacies, the important question is not what happened to Omnicare specifically. It is what this moment says about the environment every provider is operating in today.

As AI moves from pilot to operational reality, a big, looming question is taking over: How do you govern it? That question carries a lot of weight in healthcare, especially for LTC pharmacies. AI is now touching clinical decisions. Orders are being processed without a human keying every field. And regulators, at both state and federal levels, are paying close attention to what pharmacies can actually demonstrate about how their AI behaves. Getting governance right is not just a compliance exercise. It is what makes AI in pharmacy sustainable.

SoftWriters today announced the launch of FrameworkLTC+™, a major advancement in its flagship platform, FrameworkLTC™. FrameworkLTC+ introduces fully integrated, AI-driven automation built for clinical-grade accuracy, enterprise-scale performance, and production-grade reliability and security. This new solution transforms long-term care (LTC) pharmacy operations starting with one of the most manual and error-prone workflows: prescription order entry.

Cybersecurity has become a critical priority for long-term care (LTC) pharmacies. With increasing cyberattacks targeting healthcare providers, pharmacies handling sensitive patient information are particularly vulnerable. A breach or failure to safeguard data can result in severe financial and reputational damage. However, protecting a pharmacy’s infrastructure, patient data, and operational systems requires more than just technology—it starts with strong leadership.

AI is having a moment. In healthcare the pressure to “do something with AI” is everywhere. But here’s the uncomfortable truth: most AI projects fail.

In 2026, long-term care pharmacies must evolve to meet the rising demand for medication safety, compliance, and efficiency. With more medications per patient and increasing regulatory scrutiny, a data-driven medication management review process is essential to ensure safe, effective care. Here’s how FrameworkInsight can help pharmacies stay ahead.

As the Maximum Fair Price (MFP) era looms large for long-term care (LTC) pharmacies, the need for preparation has never been greater. The Inflation Reduction Act (IRA), which introduces significant changes to Medicare drug pricing, presents both a challenge and an opportunity for LTC pharmacies. Success in this new environment will depend on pharmacies' ability to adapt strategically while optimizing operations.

Long-term care pharmacies are heading into one of the most significant reimbursement shifts in years. With the first set of medications entering the Medicare Drug Price Negotiation Program on January 1, 2026, LTC pharmacies must prepare now for the operational, financial, and clinical ripple effects that come with the introduction of the Maximum Fair Price (MFP) reimbursement framework.